Company profile
TerrAscend Corp.
OTC: TSNDF · Healthcare · Drug Manufacturers - Specialty & Generic
#267 of 1,418 Healthcare companies by revenue30th-percentile growth
EA Score
55CFH 60DQ 48GM 48SS 66
v0.1 · 65/100 weight · provisional
↑ operating margin, workforce scale · ↓ disclosure history, revenue growth (YoY)
Methodology →Revenue TTM
$255.1M
Rev growth YoY (TTM)
-14.1%
Net income (FY)
-$81.3M
Employees
1,038
as of 2026-08-13
Market cap
$217.6M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$260.6M$260.6M2025
Net income-$81.3M-$81.3M2025
Operating income$42.0M$42.0M2025
Total assets$557.4M$557.4M2025
Liabilities$458.4M$458.4M2025
Equity$99.0M$99.0M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is TerrAscend Corp.’s revenue?
TerrAscend Corp. booked $260.6M in FY2025 revenue, contracting 15% year over year — slower than 70% of Healthcare companies we track, at a -31.2% net margin.
Peers · Healthcare
Iovance Biotherapeutics, Inc.59CJushi Holdings Inc.54DArvinas, Inc.61COmada Health62CMedical Facilities Corporation74BFrontage Holdings Corporation72BNeighbors
Montgomery →Key facts
CEOZiad Ghanem
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersKing of Prussia, PA
ExchangeOTC: TSNDF
Employees1,038
IPO date2017-11-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.